World Encyclopedia of Environmental History 2025
The 'World Encyclopedia of Environmental History 2025" directory has been added to ResearchAndMarkets.com's offering.
While the relationship between man and nature has been a constant feature of the human situation, the human impact on the environment has only recently because a topic of general interest to scholars and professionals in disciples across the board. Environmental history should be of great interest to anyone concerned with our present global environmental dilemmas.
The Encyclopedia of Environmental History is a worthwhile investment for those in need of a scholarly reference source on this timely topic as there are no other single works that provide comparable breadth and authoritative coverage. It is recommended for academic, public, and special libraries.
Written by a team of international experts, provides not only broad historical coverage on how human beliefs and actions have altered the natural world, but also covers the latest developments in the field. An analysis of natural phenomena and events and their impact on human societies is also included.
The environmental history of all countries is a key feature of the Encyclopedia.
With hundreds of articles, this fascinating set will prove a definitive reference source on environmental change over the course of human history, across cultures, and in the modern world. This important new work belongs in any collection serving world history, ecology, environmental studies, geography or environmental science programs.
From 'acid rain' to 'zoos', the Encyclopedia of Environmental History attempts to chronicle the human impact upon the 'natural' world (and vice versa) from prehistory to the present. It does this through hundreds of entries, ranging from geographical regions to animals and plants, environmental problems, and prominent figures in the history of environmental conservation. This collection will be a valuable first stop for undergraduate and graduate cultural ecology and physical geography research projects. The entries are concise, usually between one and five pages, and each concludes with a 'further reading' section.
Introduction
Environmental History in our Century, V. Simeonov
Human History, Energy Regimes, and the Environment, Edmund Burke III
Observations on the Nature and Culture of Environmental History, J. R. McNeill
The Promise of Global Environmental History, Sarah R. Hamilton
Urban environmental history: what lessons are there to be learnt?, Dieter Schott
Asia and the Pacific
A Synoptic Environmental History of the Island Pacific, J. R. McNeill
Australia in Global Environmental History, Libby Robin
Ecological Degradation and Environmental Crisis in China, 1800-1950, Robert B. Marks
Changes and Challenges: China's Environmental Management in Transition, Guizhen He, Yonglong Lu, Arthur P.J. Mol, Theo Beckers
Environmental History and Historiography on South Asia: Context and some Recent Publications, Michael Mann
Historical Perspectives on Forest Policy Change in Asia, David Edmunds and Eva Wollenberg
Canada
Economic Growth and Environmental Degradation in Canada, Kathleen Day and R. Quentin Grafton
The Nature of Cities: Perspectives in Canadian Urban Environmental History, Stephen Booking
South & Central America
Mexico's Environmental Revolutions, Chris Boyer and Micheline Carino
The Greater Caribbean: From Plantations to Tourism, Reinaldo Funes Monzote
The Tropical Andes: Where Multiple Visions of Nature Co-exist, Nicolas Cuvi
Nature and Territory in the Making of Brazil, Jose Augusto Padua
The La Plata Basin: Rivers, Plains, and Societies in the Southern Cone, Adrian Zarrilli
Rainforest Frontiers, Claudia Leal
Urban Nature in Latin America: Diverse Cities and Shared Narratives, Lise Sedrez
Campesinos and the Hidden History of Biodiversity, John Soluri
Hoofprints: Ranching and Landscape Transformation, Shawn Van Ausdal and Bob Wilcox
Extracting Histories: Mining, Workers, and Environment, Myrna Santiago
Prodigality and Sustainability: The Natural Sciences and the Environment, Stuart McCook
Forestry Management in Cuba: An Environmental History, Meghan Lambert
USA
Environmental History: A Road Map to Today, Professor John T. Cumbler
Gender and Environmental History, Carolyn Merchant
Landmarks of the Field in Environmental History, Louis S. Warren
New Beginning: The Counter Culture in American Environmental History, Jean-Daniel Collomb
Reconstructing the Landscape: An Environmental History, 1820-1960, David Beesley
Shades of Darkness: Race and Environmental History, Carolyn Merchant
The Justice of Ecological Restoration: Environmental History, Health, Ecology, and Justice in the United States, C. R. Palamar
The State of American Environmental History, Paul S Sutter
The Past and Present in Environmental History, Alfred W. Crosby
The Trouble with Wilderness or, Getting Back to the Wrong Nature, William Cronon
Timeline: US Environmental History
Africa
Coal and British Colonialism in Nigeria, Ihediwa Nkemjika Chimee
Demography, Environment and Conflict in West Africa, Kwesi Aning &Andrews Atta-Asamoar
Environmental Change and Policy, Melissa Leach and Robin Mearns
Environmental History of Africa, Vimbai C. Kwashirai
Environmental History with an African Edge, Jane Carruthers
False Forest History, Complicit Social Analysis:
Rethinking Some West African Environmental Narratives, James Fairhead and Melissa Leach
Arctic
The Arctic in World Environmental History, Jonathan D. Greenberg
Europe
Crisis of Feudalism: An Environmental History, Jason W. Moore.
Environmental Controversy and Environmental Awareness in Austria, Dr. Gernot Neuwirth
Environmental History and Historical Fish Populations in the Baltic, Paul Holm & Brian R. MacKenzie
Sea and the Cities towards the Environmental History of the Baltic Sea, Simo Laakkonen
Environmental History of Artificial Fertilisers in the Baltic Sea Region, Eiiand Marald.
Environmental history in the Mediterranean world: cross-disciplinary investigation of cause-and-effect for degradation and soil erosion, Karl W. Butzer
Environmental History in Europe from 1994 to 2004: Enthusiasm and Consolidation, Verena Winiwarter
Environmental History of the Danube River Basin, Verena Winiwarter, Martin Schmid, Severin Hohensinner and Gertrud Haidvogl
Environmental Movement and Environmental Politics of the Soviet Union, Neil Chapman
Exceptionalism in European Environmental History, Joachim Radkau
Gender and Environmental History: From Representations of Women and Nature To Gender Analysis of Ecology and Politics, Melissa Leach with Cathy Green
Logic of British Forest Policy, 1919-1970, Jan-Willem Oosthoek
Industry, environment and health through 200 years in Manchester, Ian Douglas, Rob Hodgson, Nigel Lawson
Resources of the City: Towards a European Urban Environmental History, Dieter Schott
Middle East & North Africa
Applying Islamic Environmental Ethics, Fazlun M. Khalid
Eco-Governance in French Algeria: Environmental History, Policy, and Colonial Administration, Diana K. Davis
How Green is Judaism? Exploring Jewish Environmental Ethics, David Vogel
Imperial Stories and Empirical Evidence, Diana K. Davis
Imperialism, Orientalism, and the Environment in the Middle East, Diana K. Davis
For more information about this directory visit https://www.researchandmarkets.com/r/qtnaba
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
[email protected] E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
Copyright Business Wire 2025.
PUB: 01/27/2025 07:18 AM/DISC: 01/27/2025 07:18 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Revolutionizing Drug Discovery: DNA-Encoded Libraries Market Set to Double Growth by 2030 with a 13.51% CAGR
The DNA-encoded Library market is driven by rising demand for efficient drug discovery methods, as DEL technology enables rapid, cost-effective screening of compounds. Key opportunities include integration with AI and ML for enhanced analysis, and increased R&D in personalized medicine, fueling DEL adoption across therapeutic areas. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "DNA-encoded Library Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The DNA-encoded Library Market was valued at USD 0.76 billion in 2024, and is expected to reach USD 1.63 billion by 2030, rising at a CAGR of 13.51%. DEL technology is revolutionizing early-stage drug discovery by enabling simultaneous screening of billions of compounds, which enhances efficiency and accelerates hit identification. As pharmaceutical and biotech companies seek scalable, cost-effective platforms for bioactive molecule discovery, DELs are gaining traction due to their high-throughput capabilities and chemical diversity. Increased R&D investment, growing interest in personalized medicine, and the demand for faster therapeutic development continue to drive adoption. Integration of artificial intelligence and machine learning into DEL workflows further enhances compound analysis, lead selection, and predictive modeling. With technological innovations in encoding chemistries and compound scaffolds, and the emergence of hybrid screening strategies, the DEL market is poised for continued robust growth. Key Market Drivers Rising Demand for Efficient Drug Discovery Methods The surge in demand for efficient drug discovery methods is a major factor driving the growth of the DEL market. Traditional drug discovery involves extensive time and financial investment, often with low success rates. DELs address this issue by enabling the rapid screening of billions of small molecules tagged with unique DNA barcodes, allowing researchers to identify promising interactions with target proteins more effectively. This method significantly reduces the time and cost associated with early-stage drug development. As pharmaceutical companies aim to speed up the development of targeted therapies for complex conditions such as cancer and neurological disorders, the scalability and precision of DEL technology offer a compelling advantage. The ability to explore vast chemical spaces and develop tailored treatments aligns with the industry's shift toward precision medicine, reinforcing DEL's role as a vital tool in modern drug discovery. Key Market Challenges Complexity of Library Design and Synthesis The intricate process of designing and synthesizing DNA-encoded libraries presents a key challenge to market growth. Creating diverse libraries requires specialized expertise in conjugating small molecules with DNA tags, with multiple synthesis steps that must be precisely executed. Maintaining the fidelity and reproducibility of libraries across large datasets is a technical hurdle, as errors in encoding can lead to inaccurate screening outcomes. Additionally, balancing chemical diversity with biological compatibility limits the scope of compound design. Some complex molecules or desired modifications may be difficult to synthesize or require extensive refinement, increasing time and costs. These complexities affect consistency and scalability, especially during transition from discovery to lead optimization. Key Market Trends Increasing Adoption of High-Throughput Screening Technologies High-throughput screening (HTS) technologies are becoming increasingly integrated with DEL platforms, enabling rapid evaluation of millions to billions of compounds. This combination boosts drug discovery efficiency by reducing time and cost while increasing hit identification accuracy. Advances in automation, robotics, and data analytics are optimizing HTS workflows, making them more adaptable to DEL applications. Artificial intelligence and machine learning algorithms are further enhancing analysis by improving target interaction predictions and prioritizing hits. These capabilities are essential in the discovery of novel therapeutics for oncology, infectious diseases, and neurological disorders, fueling broader market adoption. Key Market Players Merck KGaA GenScript Biotech Corporation Pharmaron Beijing Co., Ltd. WuXi AppTec Co., Ltd. Aurigene Pharmaceutical Services Limited BOC Sciences LGC Bioresearch Technologies SPT Labtech Ltd. Charles River Laboratories International, Inc. Life Chemicals Inc. Report Scope In this report, the Global DNA-encoded Library Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: DNA-encoded Library Market, By Product & Service: Kits & Reagents Encoded Libraries Design & Synthesis Services Screening Services Others DNA-encoded Library Market, By Therapeutic Area: Oncology Infectious Diseases Cardiovascular Diseases Neurological Diseases Autoimmune Diseases Metabolic Diseases Others DNA-encoded Library Market, By Application: Hit Generation / Identification Hit to Lead Hit Validation / Optimization Others DNA-encoded Library Market, By End Use: Academic & Research Institutes Pharmaceutical & Biotechnology Companies Contract Research Organizations Others DNA-encoded Library Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
AI-Enabled Drug Discovery and Clinical Trials Research Report 2025-2035 Featuring AiCure, Aitia, Atomwise, BenevolentAI, Insilico Medicine, PathAI, Recursion, Saama, Schroedinger, Tempus, Unlearn.ai
Discover the thriving AI-Enabled Drug Discovery and Clinical Trials Market set to exceed USD 3 billion by 2025, with projections extending to 2035. Key growth drivers include accelerated drug development timelines and cost efficiency through AI innovations such as generative models and predictive analytics. Despite challenges like regulatory compliance and data integration, the report highlights lucrative investment areas and regional market forecasts. Gain insights into market dynamics, competitive landscapes, and strategic opportunities to stay ahead in this evolving industry. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035" report has been added to world revenue for the AI-Enabled Drug Discovery and Clinical Trials Market will surpass US$3.00 billion in 2025 with strong revenue growth projected through to 2035. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new Drug Development Timelines and Cost Efficiency Driving Market GrowthKey drivers propelling the AI-enabled drug discovery and clinical trials market include the ability to reduce drug development timelines, lower research costs, and improve operational efficiency. AI technology streamlines various phases of drug discovery, including target identification, molecule screening, and clinical trial optimization, leading to faster and more cost-effective drug development. Additionally, advancements in AI-driven platforms-such as generative models for molecular design and predictive analytics for patient recruitment-are expected to further boost market growth. However, some large pharmaceutical companies remain hesitant to fully adopt AI-driven outsourcing due to concerns about data privacy, intellectual property loss, and reduced strategic control. Despite these concerns, the increasing complexity of drug development, combined with the rising costs of in-house operations, is pushing many companies to collaborate with AI solution providers to enhance efficiency and innovation. Emerging economies are also playing a critical role, as pharmaceutical firms seek to capitalize on lower operational costs and advanced AI technologies in these and Data Integration Challenges to Hamper Market GrowthWhile the adoption of AI offers significant benefits, challenges around regulatory compliance, data integration, and standardization may slow market growth. Strict regulations governing drug approval and patient data protection require AI systems to maintain transparency and explainability, adding layers of complexity to implementation. Additionally, the need for harmonized data across diverse systems and geographies poses a logistical challenge for AI-enabled real-time collaboration between AI platforms and clinical trial sites also requires robust data infrastructure and seamless integration. For instance, personalized medicine and rare disease trials require advanced AI models capable of managing vast datasets while adhering to stringent regulatory frameworks. As AI adoption grows, industry stakeholders must navigate these administrative and technical challenges to fully realize the potential of AI in drug discovery and clinical Questions Answered How is the AI-enabled drug discovery and clinical trials market evolving? What is driving and restraining the AI-enabled drug discovery and clinical trials market? How will each AI-enabled drug discovery and clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035? How will the market shares for each AI-enabled drug discovery and clinical trials submarket develop from 2025 to 2035? What will be the main driver for the overall market from 2025 to 2035? Will leading AI-enabled drug discovery and clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035? Who are the leading players and what are their prospects over the forecast period? What are the AI-enabled drug discovery and clinical trials projects for these leading companies? How will the industry evolve during the period between 2025 and 2035? What are the implications of AI-enabled drug discovery and clinical trials projects taking place now and over the next 10 years? Is there a greater need for product commercialisation to further scale the AI-enabled drug discovery and clinical trials market? Where is the AI-enabled drug discovery and clinical trials market heading and how can you ensure you are at the forefront of the market? What are the best investment options for new product and service lines? What are the key prospects for moving companies into a new growth path and C-suite? Recent Developments On 24th March 2025, researchers at the Oxford Drug Discovery Institute have employed AI-powered databases to accelerate Alzheimer's drug discovery. By efficiently analyzing extensive biomedical data, they identified 54 immune system-related genes for potential testing, significantly reducing the time required for gene evaluation and expediting the identification of promising drug targets. On 21st March 2025, AstraZeneca announced a $2.5 billion investment over five years to establish a research and manufacturing center in Beijing, featuring an AI and data science laboratory. This initiative underscores the company's commitment to leveraging AI for enhancing early-stage research and clinical development, aiming to expedite drug discovery and reduce associated costs. On 8th January 2025, Advanced Micro Devices Inc. (AMD) invested $20 million in Absci Corp to enhance AI-backed drug discovery efforts. This collaboration aims to expedite biologics innovation and reduce costs by leveraging AMD's advanced computing capabilities, highlighting the growing role of AI in transforming traditional drug development processes. Leading Companies Profiled AiCure Aitia Atomwise Inc. BenevolentAI Insilico Medicine PathAI, Inc. Recursion Saama Technologies Schroedinger, Inc. Tempus Inc. Key Topics Covered: 1 Report Overview1.1 Objectives of the Study1.2 Introduction to AI-Enabled Drug Discovery and Clinical Trials Market1.3 What This Report Delivers1.4 Why You Should Read This Report1.5 Key Questions Answered by This Analytical Report1.6 Who is This Report for?1.7 Methodology1.8 Frequently Asked Questions (FAQs)1.9 Associated Reports1.10 About the Publisher2 Executive Summary3 Market Overview3.1 Key Findings3.2 Market Dynamics3.3 Impact Analysis3.3.1 Market Driving Factors3.3.1.1 Growing Focus on Personalized Medicine3.3.1.2 Advancements in Technology3.3.1.3 Growing Adoption of AI in Healthcare3.3.2 Market Restraining Factors3.3.2.1 Limited Data Availability and Quality3.3.2.2 Integration with Existing Infrastructure3.3.2.3 Concerns over Data Privacy and Security3.3.3 Market Opportunities3.3.3.1 Improved Patient Outcomes3.3.3.2 Increasing AI adoption in Pharma and Biopharma Clinical Trials3.3.3.3 Growing Collaborations and Partnerships3.4 Regulatory Framework3.5 Emerging Markets and Megatrends3.6 Porter's Five Forces Analysis3.7 PEST Analysis4 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Component4.1 Key Findings4.2 Component Segment: Market Attractiveness Index4.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Component4.4 Services4.4.1 Market Size by Region, 2025-2035 (US$ Million)4.4.2 Market Share by Region, 2025 & 2035 (%)4.5 Software Solutions5 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Application5.1 Key Findings5.2 Application Segment: Market Attractiveness Index5.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Application5.4 Clinical Trials5.4.1 Market Size by Region, 2025-2035 (US$ Million)5.4.2 Market Share by Region, 2025 & 2035 (%)5.5 Drug Design5.6 Data Aggregation and Analysis5.7 Drug Characterization5.8 Biomarker Research5.9 Others6 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Therapeutic Area6.1 Key Findings6.2 Therapeutic Area Segment: Market Attractiveness Index6.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by Therapeutic Area6.4 Oncology6.4.1 Market Size by Region, 2025-2035 (US$ Million)6.4.2 Market Share by Region, 2025 & 2035 (%)6.5 Cardiovascular Diseases6.6 Infectious Diseases6.7 Neurodegenerative Diseases6.8 Metabolic Diseases6.9 Immunological Disorders6.10 Others7 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by End-users7.1 Key Findings7.2 End-users Segment: Market Attractiveness Index7.3 AI-Enabled Drug Discovery and Clinical Trials Market Size Estimation and Forecast by End-users7.4 Pharmaceutical & Biopharmaceutical Companies7.4.1 Market Size by Region, 2025-2035 (US$ Million)7.4.2 Market Share by Region, 2025 & 2035 (%)7.5 Contract Research Organizations (CROs)7.6 Academic Institutes and Research Centre8 AI-Enabled Drug Discovery and Clinical Trials Market Analysis by Region8.1 Key Findings8.2 Regional Market Size Estimation and Forecast For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment
Discover the future of the Molecular Diagnostics - Infectious Disease sector with our comprehensive report. Explore how multiplex assays and rapid testing are transforming diagnosis and treatment amidst the boom in biotechnology and genomics. This detailed analysis covers dynamic trends such as pathogen evolution, globalization, and climate change impacts. Benefit from extensive insights, including U.S. Medicare Fee Schedules, and detailed global data. Equip your organization with expert knowledge today. Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" report has been added to offering. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report - and find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any country in the world is available to purchasers of the report. This research makes you the expert in your organization. Assistance and additional specific data is provided without additional charges. All report data is available in Excel format on request. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this report. A range of dynamic trends are pushing market growth and company valuations. Trends like: Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides1.1 Situation Analysis2 Introduction and Market Definition2.1 Market Definition2.1.1 Market Size2.1.2 Currency2.1.3 Years2.2 Methodology2.2.1 Methodology2.2.2 Sources2.2.3 Authors2.3 Perspective: Healthcare Spending2.3.1 Global Healthcare Spending2.3.2 Spending on Healthcare and Pharmaceuticals2.3.3 Spending on Diagnostics2.3.4 Important Role of Insurance for Medical Services2.4 The Nature of the IVD Product2.4.1 Features Overview2.4.2 The Misunderstood Feature2.4.3 Regulation2.4.4 The Newest Feature2.4.5 The Oldest Feature2.4.6 All About Scope2.4.7 Why Turnaround is Becoming More Important2.4.8 The Role of Trust2.5 The IVD Product of the Future3 Infectious Diseases - Guide to the Pathogens3.1 Infectious Disease Pathogens - The Big Picture3.1.1 Viruses3.1.2 Bacteria3.1.3 Fungi3.1.4 Parasites3.1.5 Prions3.1.6 Virulence3.1.7 Transmission3.2 The Coronavirus3.2.1 Severe acute respiratory syndrome (SARS)3.2.2 Middle East respiratory syndrome (MERS)3.2.3 COVID-19. The SARS CoV 2 Virus3.2.3.1 Signs and symptoms3.2.3.2 Transmission3.2.3.3 Diagnosis3.2.3.4 Prevention3.2.3.5 Management3.2.3.6 Prognosis4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body4.2 The Clinical Laboratory Market Segments4.2.1 Traditional Market Segmentation4.2.2 Laboratory Focus and Segmentation4.2.3 Segmenting the Syndromic Testing Market4.3 Industry Structure4.3.1 Hospital Testing Share4.3.2 Economies of Scale4.3.3 Hospital vs. Central Lab4.3.4 Physician Office Lab's4.3.5 Physician's and POCT5 Market Trends5.1 Factors Driving Growth5.1.1 The Nucleic Acid Impact5.1.2 Population Dynamics5.1.3 The Developing World5.1.4 Decentralization5.1.5 Self Testing5.1.6 The Need for Speed5.2 Factors Limiting Growth5.2.1 Costs and Experience Curve Effects5.2.2 The Role of ID Prevalence5.2.3 Wellness5.2.4 The Impact of Living Standards5.3 Instrumentation, Automation and Diagnostic Trends5.3.1 Traditional Automation and Centralization5.3.2 The New Automation, Decentralization and Point of Care5.3.3 Instruments Key to Market Share5.3.4 Bioinformatics Plays a Role5.3.5 PCR Takes Command5.3.6 Next Generation Sequencing Fuels a Revolution5.3.7 NGS Impact on Pricing5.3.8 Whole Genome Sequencing, A Brave New World5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment6 Clinical Laboratory MDx Infectious Disease Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Presymptom Health Nabs Funding for Sepsis Test6.3 FDA Clears BioMerieux GI Panel6.4 Rapid Infection Diagnostic Launches BSIDx6.5 Biotia's AI-, Sequencing-Based UTI Test approved6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic6.7 Roche Respiratory Panel Receives FDA EUA6.8 Genetic Signatures Gets Approval for GI Parasite Panel6.9 Diasorin Expands Respiratory Panel6.10 BioMerieux Outlines MDx-Driven Growth6.11 T2 Biosystems Gets Extended T2Bacteria Panel6.12 Diasorin Aims to Deliver Updated Instruments, New Assays6.13 Oxford Nanopore Nabs Investment From BioMerieux6.14 Day Zero Diagnostics Closes Financing Round6.15 Spindiag Seeks Investors for Rapid PCR System6.16 Sorrento Therapeutics Nabs Contract for Dx Platform6.17 Kephera Planning Menu of Infectious Disease Tests6.18 Oxford Nanopore and BioMerieux to Develop IDDx6.19 SD Biosensor Eyes Global Expansion6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance6.21 Takara Developing High-Throughput Multiplex Panels6.22 BioGX Debuts New Point-of-Care Molecular Testing System6.23 Nanopath MDx Platform Providing 15-Minute Results6.24 ProtonDx Commercializing Rapid MDx Instrument6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS6.27 Accelerate Diagnostics Anticipates Growth6.28 Lumos Diagnostics Expanding Test Portfolio6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens7 Key Companies7.1 Abbott Laboratories7.2 Agilent7.3 Altona Diagnostics7.4 Anitoa7.5 Autonomous Medical Devices7.6 Beckman Coulter Diagnostics (Danaher)7.7 Becton, Dickinson and Company7.8 BioGX7.9 Biomatik7.10 bioMerieux Diagnostics7.11 Bio-Rad Laboratories, Inc.7.12 Cepheid (Danaher)7.13 Diasorin S.p.A.7.14 DNAe7.15 Flow Health7.16 Global Access Diagnostics7.17 Great Basin Scientific, Inc.7.18 Hologic7.19 Novacyt7.20 Novus Diagnostics7.21 Oncimmune7.22 One Codex7.23 OraSure Technologies7.24 Prometheus Laboratories7.25 Qiagen7.26 QuidelOrtho7.27 R-Biopharm AG7.28 Response Biomedical7.29 Revvity7.30 Roche Diagnostics7.31 Siemens Healthineers7.32 Thermo Fisher Scientific7.33 Vela Diagnostics7.34 Veredus Laboratories7.35 YD Diagnostics7.36 Zhejiang Orient Gene Biotech8 The Global Market for Clinical Laboratory MDx Infectious Disease8.1 Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Place - Overview9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application9.1 Respiratory9.2 Blood Borne Virus9.3 Transplant9.4 Hospital Acquired Infections9.5 Reproductive Health9.6 C19 Singleplex9.7 Meningitis9.8 Gastrointestinal9.9 Tropical10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place10.1 Hospital Lab10.2 Outpatient Lab10.3 Point of Care10.4 Other Place11 Appendices11.1 Growth of Approved IVD Test Menu11.2 Growth of Approved Average IVD Test Fee11.3 The Most Used IVD Assays11.4 The Highest Grossing Assays11.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
